Drug intelligence / Profile preview

levocarnitine

Development stage
Approved
Lead developer
Ain Shams University
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

Levocarnitine (L-carnitine) is a naturally occurring small molecule and a derivative of the amino acid lysine, essential for energy metabolism. It acts as a carrier molecule that facilitates the transport of long-chain fatty acids across the inner mitochondrial membrane into the mitochondrial matrix for beta-oxidation, while also assisting in the removal of toxic metabolic byproducts. In a Phase 2 clinical trial conducted by Ain Shams University, levocarnitine is being investigated for its cardioprotective potential in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The study evaluates its efficacy in reducing myocardial reperfusion injury by monitoring biomarkers such as nitrotyrosine (an oxidative stress marker) and Matrix metallopeptidase-2 (MMP-2, a marker of cardiac fibrosis).

Brand names
L-Carnitine 1 gm / 5 mL InjectionCarnitol
Other names
L-carnitinelevocarnitine
02

Targets

SLC7A1 (Cationic amino acid transporter 1)CPT2 (Carnitine O-palmitoyltransferase 2)SLC22A5 (Organic cation/carnitine transporter 2)

Beyond the preview

Go deeper on levocarnitine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levocarnitine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call